1. At least 50% of consumers are willing to share their health data with Google, Microsoft, Samsung, and Apple, according to the annual Mary Meeker Internet Trends Report.
2. The CEOs of Novartis and Allergan said they expect the Trump administration to have proposals addressing high drug prices by as early this month. (Bloomberg)
3. The FDA approved the first generic versions of Eli Lilly’s ADHD drug Strattera. The generic drugmakers marketing Strattera are Apotex, Teva Pharmaceutical Industries, Aurobindo Pharma, and Glenmark.
4. Amgen filed a lawsuit against the FDA for allegedly rejecting to grant six months of pediatric exclusivity and patent protection for its hyperparathyroidism drug Sensipar. (Life Sciences Intellectual Property Review)
5. Mylan reportedly overcharged the U.S. government by about $1.27 billion for its EpiPen autoinjectors between 2006 and 2016, according to an analysis by the Department of Health and Human Services. (Reuters)
